ProCE Banner Activity

Novos dados sobre os inibidores de BTK para LLC e LCM: especialistas discutem o EHA 2022

Clinical Thought
Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados no EHA 2022 sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Released: August 15, 2022

Expiration: August 14, 2023

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor: AbbVie, Gilead Sciences, Janssen-Cilag, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.